Ab Rahman Norazida, Low Ee Vien, Kamaruddin Fateha, Che Ayub Asilah, Chong Sue Chin, Tumiran Noridayu, Idris Norafidah
Institute for Clinical Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.
Institute for Health System Research, National Institutes of Health, Ministry of Health Malaysia, Shah Alam, Malaysia.
J Pharm Policy Pract. 2025 Jul 15;18(1):2528244. doi: 10.1080/20523211.2025.2528244. eCollection 2025.
Medication errors (MEs) represent avoidable harm that occurs within the healthcare system. While most MEs do not pose significant safety threats, some can result in severe harm, disability, or even death for patients. We aimed to describe the prevalence, characteristics, and outcomes of MEs due to transcribing errors.
Retrospective analysis of data from the Medication Error Reporting System (MERS) in Malaysia. All ME reports submitted to MERS were verified and classified by trained pharmacists from the Ministry of Health Malaysia. Transcribing errors were identified from all ME reports submitted to MERS that were classified as 'data entry error'. All data from public health facilities (hospitals and clinics) submitted in 2018-2022 were included in the analysis. Descriptive analyses were conducted on frequencies and characteristics of the transcribing errors.
From January 2018 to December 2022, 265,194 MEs were reported to the MERS, of which 12,049 (4.5%) were transcribing errors. The large proportion of transcribing error was related to dose error, i.e. incorrect dose (48.6%) and incorrect frequency (19.9%), followed by drug error (incorrect drug, 13.3% and incorrect patient, 6.3%). The majority of the errors do not reach patients (94.8%). The most possible error causes and contributing factors were work and environment followed by staff factors, task and technology, and medication-related.
There was an increase in voluntary reporting over the years, reflecting a growing culture of reporting among healthcare professionals. These findings offer valuable insights into medication errors caused by transcribing processes in Malaysia, which can inform efforts to improve pharmacy practices, design appropriate interventions, and reduce harm to patients.
用药错误(MEs)是医疗系统中可避免的伤害。虽然大多数用药错误不会构成重大安全威胁,但有些可能会给患者带来严重伤害、残疾甚至死亡。我们旨在描述因转录错误导致的用药错误的发生率、特征和后果。
对马来西亚用药错误报告系统(MERS)的数据进行回顾性分析。所有提交给MERS的用药错误报告均由马来西亚卫生部训练有素的药剂师进行核实和分类。从提交给MERS且被归类为“数据录入错误”的所有用药错误报告中识别转录错误。分析纳入了2018 - 2022年提交的来自公共卫生机构(医院和诊所)的所有数据。对转录错误的频率和特征进行描述性分析。
2018年1月至2022年12月,向MERS报告了265,194例用药错误,其中12,049例(4.5%)为转录错误。转录错误的很大一部分与剂量错误有关,即剂量不正确(48.6%)和频率不正确(19.9%),其次是药物错误(药物不正确,13.3%和患者不正确,6.3%)。大多数错误未影响到患者(94.8%)。最可能的错误原因和促成因素是工作和环境,其次是人员因素、任务和技术以及与药物相关的因素。
多年来自愿报告有所增加,反映出医疗专业人员中报告文化的日益浓厚。这些发现为马来西亚转录过程导致的用药错误提供了有价值的见解,可为改善药房实践、设计适当干预措施以及减少对患者的伤害提供参考。